Modulation of androgen receptor signaling in hormonal therapy-resistant prostate cancer cell lines

PLoS ONE

Volumn 6, Issue 8, 2011, Pages

  Marques, Rute B ^a   Dits, Natasja F ^a   Erkens Schulze, Sigrun ^a   van IJcken, Wilfred F J ^b   van Weerden, Wytske M ^a   Jenster, Guido ^a  

^a JOSEPHINE NEFKENS INSTITUTE   (Netherlands)

^b ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ADENINE; ANDROGEN; ANDROGEN RECEPTOR; ANTIANDROGEN; HYDROXYFLUTAMIDE; METRIBOLONE; THYMINE; TUMOR MARKER; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; DRUG DERIVATIVE; FLUTAMIDE; PRIMER DNA;

ACSL3 GENE; ARTICLE; CANCER CELL; CANCER GRADING; CANCER GROWTH; CANCER HORMONE THERAPY; CANCER RESISTANCE; CELL ADHESION; CELL DIFFERENTIATION; CELL FUNCTION; CELL PROLIFERATION; CELL SECRETION; CONTROLLED STUDY; CYTOSKELETON; ENDOD1 GENE; GENE CONTROL; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENE MUTATION; GENE OVEREXPRESSION; GENE TARGETING; GENETIC TRANSCRIPTION; HORMONE ACTION; HORMONE RESPONSE; HUMAN; HUMAN CELL; MARKER GENE; MCCC2 GENE; METASTASIS; NUCLEOTIDE SEQUENCE; PROSTATE CANCER; PROTEIN MODIFICATION; RECEPTOR DOWN REGULATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; UNINDEXED SEQUENCE; UPREGULATION; DNA MICROARRAY; DRUG RESISTANCE; GENETICS; MALE; METABOLISM; PROSTATE TUMOR; TUMOR CELL LINE; VALIDATION STUDY;

ANDROGEN ANTAGONISTS; ANTINEOPLASTIC AGENTS, HORMONAL; BASE SEQUENCE; CELL LINE, TUMOR; DNA PRIMERS; DRUG RESISTANCE, NEOPLASM; FLUTAMIDE; GENE EXPRESSION PROFILING; HUMANS; MALE; METRIBOLONE; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION;

EID: 79961163502     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0023144     Document Type: Article

References (71)

1. Ferlay J, Autier P, Boniol M, Heanue M, Colombet M, et al. (2007) Estimates of the cancer incidence and mortality in Europe in 2006. Ann Oncol 18: 581-592.
2. Frydenberg M, Stricker PD, Kaye KW, (1997) Prostate cancer diagnosis and management. Lancet 349: 1681-1687.
3. Crawford ED, Eisenberger MA, McLeod DG, Spaulding JT, Benson R, et al. (1989) A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. N Engl J Med 321: 419-424.
4. Eisenberger MA, Blumenstein BA, Crawford ED, Miller G, McLeod DG, et al. (1998) Bilateral orchiectomy with or without flutamide for metastatic prostate cancer. N Engl J Med 339: 1036-1042.
5. Prins GS, Sklarew RJ, Pertschuk LP, (1998) Image analysis of androgen receptor immunostaining in prostate cancer accurately predicts response to hormonal therapy. J Urol 159: 641-649.
6. Jenster G, (1999) The role of the androgen receptor in the development and progression of prostate cancer. Semin Oncol 26: 407-421.
7. Devlin HL, Mudryj M, (2009) Progression of prostate cancer: multiple pathways to androgen independence. Cancer Lett 274: 177-186.
8. Marques RB, Erkens-Schulze S, de Ridder CM, Hermans KG, Waltering K, et al. (2005) Androgen receptor modifications in prostate cancer cells upon long-term androgen ablation and antiandrogen treatment. Int J Cancer 117: 221-229.
9. Baugh LR, Hill AA, Brown EL, Hunter CP, (2001) Quantitative analysis of mRNA amplification by in vitro transcription. Nucleic Acids Res 29: E29.
10. Smyth GK, (2005) Limma: linear models for microarray data; Gentleman R, Carey V, Dudoit S, Irizarry R, Huber W, editors. New York Springer pp. 397-420.
11. Smyth GK, Speed T, (2003) Normalization of cDNA microarray data. Methods 31: 265-273.
12. Veldhoven A, de Lange D, Smid M, de Jager V, Kors JA, et al. (2005) Storing, linking, and mining microarray databases using SRS. BMC Bioinformatics 6: 192.
13. DePrimo SE, Diehn M, Nelson JB, Reiter RE, Matese J, et al. (2002) Transcriptional programs activated by exposure of human prostate cancer cells to androgen. Genome Biol 3: RESEARCH0032.
14. Hendriksen PJ, Dits NF, Kokame K, Veldhoven A, van Weerden WM, et al. (2006) Evolution of the androgen receptor pathway during progression of prostate cancer. Cancer Res 66: 5012-5020.
15. Nelson PS, Clegg N, Arnold H, Ferguson C, Bonham M, et al. (2002) The program of androgen-responsive genes in neoplastic prostate epithelium. Proc Natl Acad Sci U S A 99: 11890-11895.
16. Nickols NG, Dervan PB, (2007) Suppression of androgen receptor-mediated gene expression by a sequence-specific DNA-binding polyamide. Proc Natl Acad Sci U S A 104: 10418-10423.
17. Wang Q, Li W, Liu XS, Carroll JS, Janne OA, et al. (2007) A hierarchical network of transcription factors governs androgen receptor-dependent prostate cancer growth. Mol Cell 27: 380-392.
18. Best CJ, Gillespie JW, Yi Y, Chandramouli GV, Perlmutter MA, et al. (2005) Molecular alterations in primary prostate cancer after androgen ablation therapy. Clin Cancer Res 11: 6823-6834.
19. Chandran UR, Ma C, Dhir R, Bisceglia M, Lyons-Weiler M, et al. (2007) Gene expression profiles of prostate cancer reveal involvement of multiple molecular pathways in the metastatic process. BMC Cancer 7: 64.
20. Lapointe J, Li C, Higgins JP, van de Rijn M, Bair E, et al. (2004) Gene expression profiling identifies clinically relevant subtypes of prostate cancer. Proc Natl Acad Sci U S A 101: 811-816.
21. Singh D, Febbo PG, Ross K, Jackson DG, Manola J, et al. (2002) Gene expression correlates of clinical prostate cancer behavior. Cancer Cell 1: 203-209.
22. Tamura K, Furihata M, Tsunoda T, Ashida S, Takata R, et al. (2007) Molecular features of hormone-refractory prostate cancer cells by genome-wide gene expression profiles. Cancer Res 67: 5117-5125.
23. Varambally S, Yu J, Laxman B, Rhodes DR, Mehra R, et al. (2005) Integrative genomic and proteomic analysis of prostate cancer reveals signatures of metastatic progression. Cancer Cell 8: 393-406.
24. Yu YP, Landsittel D, Jing L, Nelson J, Ren B, et al. (2004) Gene expression alterations in prostate cancer predicting tumor aggression and preceding development of malignancy. J Clin Oncol 22: 2790-2799.
25. Dennis G Jr, Sherman BT, Hosack DA, Yang J, Gao W, et al. (2003) DAVID: Database for Annotation, Visualization, and Integrated Discovery. Genome Biol 4: P3.
26. Huang da W, Sherman BT, Lempicki RA, (2009) Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc 4: 44-57.
27. van der Heul-Nieuwenhuijsen L, Dits NF, Jenster G, (2009) Gene expression of forkhead transcription factors in the normal and diseased human prostate. BJU Int 103: 1574-1580.
28. Dhanasekaran SM, Barrette TR, Ghosh D, Shah R, Varambally S, et al. (2001) Delineation of prognostic biomarkers in prostate cancer. Nature 412: 822-826.
29. Rubin MA, Bismar TA, Andren O, Mucci L, Kim R, et al. (2005) Decreased alpha-methylacyl CoA racemase expression in localized prostate cancer is associated with an increased rate of biochemical recurrence and cancer-specific death. Cancer Epidemiol Biomarkers Prev 14: 1424-1432.
30. Attard G, Clark J, Ambroisine L, Mills IG, Fisher G, et al. (2008) Heterogeneity and clinical significance of ETV1 translocations in human prostate cancer. Br J Cancer 99: 314-320.
31. Marques RB, Dits NF, Erkens-Schulze S, van Weerden WM, Jenster G, Bypass mechanisms of the androgen receptor pathway in therapy-resistant prostate cancer cell models. PLoS One 5.
32. Tararova ND, Narizhneva N, Krivokrisenko V, Gudkov AV, Gurova KV, (2007) Prostate cancer cells tolerate a narrow range of androgen receptor expression and activity. Prostate 67: 1801-1815.
33. Chen CD, Welsbie DS, Tran C, Baek SH, Chen R, et al. (2004) Molecular determinants of resistance to antiandrogen therapy. Nat Med 10: 33-39.
34. Culig Z, Hoffmann J, Erdel M, Eder IE, Hobisch A, et al. (1999) Switch from antagonist to agonist of the androgen receptor bicalutamide is associated with prostate tumour progression in a new model system. Br J Cancer 81: 242-251.
35. Kokontis JM, Hay N, Liao S, (1998) Progression of LNCaP prostate tumor cells during androgen deprivation: hormone-independent growth, repression of proliferation by androgen, and role for p27Kip1 in androgen-induced cell cycle arrest. Mol Endocrinol 12: 941-953.
36. Kokontis J, Takakura K, Hay N, Liao S, (1994) Increased androgen receptor activity and altered c-myc expression in prostate cancer cells after long-term androgen deprivation. Cancer Res 54: 1566-1573.
37. Dehm SM, Tindall DJ, (2006) Ligand-independent androgen receptor activity is activation function-2-independent and resistant to antiandrogens in androgen refractory prostate cancer cells. J Biol Chem 281: 27882-27893.
38. Waltering KK, Helenius MA, Sahu B, Manni V, Linja MJ, et al. (2009) Increased expression of androgen receptor sensitizes prostate cancer cells to low levels of androgens. Cancer Res 69: 8141-8149.
39. Veldscholte J, Ris-Stalpers C, Kuiper GG, Jenster G, Berrevoets C, et al. (1990) A mutation in the ligand binding domain of the androgen receptor of human LNCaP cells affects steroid binding characteristics and response to anti-androgens. Biochem Biophys Res Commun 173: 534-540.
40. Chandran UR, Dhir R, Ma C, Michalopoulos G, Becich M, et al. (2005) Differences in gene expression in prostate cancer, normal appearing prostate tissue adjacent to cancer and prostate tissue from cancer free organ donors. BMC Cancer 5: 45.
41. Waghray A, Schober M, Feroze F, Yao F, Virgin J, et al. (2001) Identification of differentially expressed genes by serial analysis of gene expression in human prostate cancer. Cancer Res 61: 4283-4286.
42. van der Kwast TH, Schalken J, Ruizeveld de Winter JA, van Vroonhoven CC, Mulder E, et al. (1991) Androgen receptors in endocrine-therapy-resistant human prostate cancer. Int J Cancer 48: 189-193.
43. Ruizeveld de Winter JA, Janssen PJ, Sleddens HM, Verleun-Mooijman MC, Trapman J, et al. (1994) Androgen receptor status in localized and locally progressive hormone refractory human prostate cancer. Am J Pathol 144: 735-746.
44. Brown RS, Edwards J, Dogan A, Payne H, Harland SJ, et al. (2002) Amplification of the androgen receptor gene in bone metastases from hormone-refractory prostate cancer. J Pathol 198: 237-244.
45. Koivisto P, Kononen J, Palmberg C, Tammela T, Hyytinen E, et al. (1997) Androgen receptor gene amplification: a possible molecular mechanism for androgen deprivation therapy failure in prostate cancer. Cancer Res 57: 314-319.
46. Linja MJ, Savinainen KJ, Saramaki OR, Tammela TL, Vessella RL, et al. (2001) Amplification and overexpression of androgen receptor gene in hormone-refractory prostate cancer. Cancer Res 61: 3550-3555.
47. Bostwick DG, (1994) Prostate-specific antigen. Current role in diagnostic pathology of prostate cancer. Am J Clin Pathol 102: S31-37.
48. Sterbis JR, Gao C, Furusato B, Chen Y, Shaheduzzaman S, et al. (2008) Higher expression of the androgen-regulated gene PSA/HK3 mRNA in prostate cancer tissues predicts biochemical recurrence-free survival. Clin Cancer Res 14: 758-763.
49. Tomlins SA, Mehra R, Rhodes DR, Cao X, Wang L, et al. (2007) Integrative molecular concept modeling of prostate cancer progression. Nat Genet 39: 41-51.
50. Mendiratta P, Mostaghel E, Guinney J, Tewari AK, Porrello A, et al. (2009) Genomic Strategy for Targeting Therapy in Castration-Resistant Prostate Cancer. J Clin Oncol.
51. Brooke GN, Parker MG, Bevan CL, (2008) Mechanisms of androgen receptor activation in advanced prostate cancer: differential co-activator recruitment and gene expression. Oncogene 27: 2941-2950.
52. Chmelar R, Buchanan G, Need EF, Tilley W, Greenberg NM, (2007) Androgen receptor coregulators and their involvement in the development and progression of prostate cancer. Int J Cancer 120: 719-733.
53. Culig Z, Hobisch A, Cronauer MV, Hittmair A, Radmayr C, et al. (1995) Activation of the androgen receptor by polypeptide growth factors and cellular regulators. World J Urol 13: 285-289.
54. York TP, Plymate SR, Nelson PS, Eaves LJ, Webb HD, et al. (2005) cDNA microarray analysis identifies genes induced in common by peptide growth factors and androgen in human prostate epithelial cells. Mol Carcinog 44: 242-251.
55. Tomlins SA, Rhodes DR, Perner S, Dhanasekaran SM, Mehra R, et al. (2005) Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 310: 644-648.
56. Shimizu K, Ichikawa H, Tojo A, Kaneko Y, Maseki N, et al. (1993) An ets-related gene, ERG, is rearranged in human myeloid leukemia with t(16;21) chromosomal translocation. Proc Natl Acad Sci U S A 90: 10280-10284.
57. Ida K, Kobayashi S, Taki T, Hanada R, Bessho F, et al. (1995) EWS-FLI-1 and EWS-ERG chimeric mRNAs in Ewing's sarcoma and primitive neuroectodermal tumor. Int J Cancer 63: 500-504.
58. Simpson S, Woodworth CD, DiPaolo JA, (1997) Altered expression of Erg and Ets-2 transcription factors is associated with genetic changes at 21q22.2-22.3 in immortal and cervical carcinoma cell lines. Oncogene 14: 2149-2157.
59. Han B, Mehra R, Dhanasekaran SM, Yu J, Menon A, et al. (2008) A fluorescence in situ hybridization screen for E26 transformation-specific aberrations: identification of DDX5-ETV4 fusion protein in prostate cancer. Cancer Res 68: 7629-7637.
60. Tomlins SA, Laxman B, Dhanasekaran SM, Helgeson BE, Cao X, et al. (2007) Distinct classes of chromosomal rearrangements create oncogenic ETS gene fusions in prostate cancer. Nature 448: 595-599.
61. Maher CA, Kumar-Sinha C, Cao X, Kalyana-Sundaram S, Han B, et al. (2009) Transcriptome sequencing to detect gene fusions in cancer. Nature 458: 97-101.
62. Tomlins SA, Bjartell A, Chinnaiyan AM, Jenster G, Nam RK, et al. (2009) ETS gene fusions in prostate cancer: from discovery to daily clinical practice. Eur Urol 56: 275-286.
63. Tomlins SA, Laxman B, Varambally S, Cao X, Yu J, et al. (2008) Role of the TMPRSS2-ERG gene fusion in prostate cancer. Neoplasia 10: 177-188.
64. Carver BS, Tran J, Gopalan A, Chen Z, Shaikh S, et al. (2009) Aberrant ERG expression cooperates with loss of PTEN to promote cancer progression in the prostate. Nat Genet 41: 619-624.
65. King JC, Xu J, Wongvipat J, Hieronymus H, Carver BS, et al. (2009) Cooperativity of TMPRSS2-ERG with PI3-kinase pathway activation in prostate oncogenesis. Nat Genet 41: 524-526.
66. Compagno D, Merle C, Morin A, Gilbert C, Mathieu JR, et al. (2007) SIRNA-directed in vivo silencing of androgen receptor inhibits the growth of castration-resistant prostate carcinomas. PLoS ONE 2: e1006.
67. Liao X, Tang S, Thrasher JB, Griebling TL, Li B, (2005) Small-interfering RNA-induced androgen receptor silencing leads to apoptotic cell death in prostate cancer. Mol Cancer Ther 4: 505-515.
68. Haag P, Bektic J, Bartsch G, Klocker H, Eder IE, (2005) Androgen receptor down regulation by small interference RNA induces cell growth inhibition in androgen sensitive as well as in androgen independent prostate cancer cells. J Steroid Biochem Mol Biol 96: 251-258.
69. Cheng H, Snoek R, Ghaidi F, Cox ME, Rennie PS, (2006) Short hairpin RNA knockdown of the androgen receptor attenuates ligand-independent activation and delays tumor progression. Cancer Res 66: 10613-10620.
70. Furutani T, Takeyama K, Koutoku H, Ito S, Taniguchi N, et al. (2005) A role of androgen receptor protein in cell growth of an androgen-independent prostate cancer cell line. Biosci Biotechnol Biochem 69: 2236-2239.
71. Snoek R, Cheng H, Margiotti K, Wafa LA, Wong CA, et al. (2009) In vivo knockdown of the androgen receptor results in growth inhibition and regression of well-established, castration-resistant prostate tumors. Clin Cancer Res 15: 39-47.